Predicine

Join Predicine at the 2024 36th EORTC-NCI-AACR Symposium in Barcelona, Spain, from October 23-25! Visit us at booth #19 to discover how our innovative liquid biopsy solutions accelerate drug development by enhancing patient enrollment, monitoring drug efficacy, and identifying resistance mechanisms — advancing clinical trials from early-phase to pivotal stages.     Connect with our team to learn how Predicine’s accurate, accessible, and affordable liquid biopsy solutions, backed by our global network of centralized labs and decentralized CDx and kit manufacturing capabilities, are driving global clinical trials, biomarker discovery, and CDx development in the US, EU, China, and beyond.    Schedule a meeting with us here: https://lnkd.in/gtCKVQwk Learn more about Predicine: https://lnkd.in/gndzmpGH #Predicine #Diagnostics #Oncology #NGS #LiquidBiopsy #MRD #ctDNA #CDx #PrecisionMedicine 

October is Breast Cancer Awareness Month, a time to recognize 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime. According to the National Breast Cancer Foundation, this year alone, an estimated 297,790 women and 2,800 men will face a breast cancer diagnosis.     Early detection plays a crucial role, and advancements in treatment have significantly improved survival rates.  Together, we can raise awareness, encourage early detection, and offer support to those affected by breast cancer.    Learn more about how Predicine’s liquid biopsy technology is transforming personalized breast cancer care: Variant allele frequency in circulating tumor DNA correlates with tumor burden and predicts outcomes in patients with advanced breast cancer https://lnkd.in/gUxR87Zp    #liquidbiopsy #breastcancerawarenessmonth #breastcancer #MBC #companiondiagnostic #CDx #nextgenerationsequencing #NGS #comprehensivegenomicprofiling #medicaloncologists 

Predicine is in Oaks, Pennsylvania, attending the Merck Technology Symposium! Connect with our team at booth #625 to learn how Predicine's Accurate, Accessible, and Affordable (AAA) liquid biopsy solutions can empower your global clinical trials across the US, EU, Japan, China, and beyond.

Exciting new data about the utility of PredicineCARE™ and PredicineSCORE™ was presented at #ESMO2024, highlighting opportunities to enhance cancer care for more patients.  Visit us at booth #419 to discover more about three recent studies showcasing how Predicine’s liquid biopsy technology accelerates and empowers global clinical trials.    • PredicineCARE™: With FDA Breakthrough Device Designation (BDD), learn how the urine-based NGS test accelerates patient recruitment in Janssen’s TAR-210 trial for early-stage bladder cancer. • PredicineCARE™: See how AR status analysis using this assay supported BMS in evaluating therapy efficacy across subgroups in the clinical trial of BMS-986365 for metastatic castration-resistant prostate cancer (mCRPC). • PredicineSCORE™: Discover the potential predictive power of this liquid biopsy assay in Incyte’s Phase 1 trial of INCB123667, a selective CDK2 inhibitor for advanced solid tumors.    #ESMO2024 #PredicineSCORE #CDK2Inhibitor #FGFR # AR #bladdercaner # mCRPC #PrecisionMedicine #OncologyResearch #CancerTherapeutics #LiquidBiopsy    

Attending ESMO 2024 in Barcelona? Visit Predicine at booth #419 to learn how the PredicineCARE™ cfDNA assay is advancing clinical trials and providing valuable insights into HR+/HER2- breast cancer with comprehensive genetic profiling.     Key Highlights of PredicineCARE™:   - FDA Breakthrough Device Designation: Granted in 2022.  - New York State Approval: Achieved in 2024.  - CDx Development Collaborations: Partnering with Janssen, Apollomics, and other leading pharmaceutical companies.    Connect with our team at booth #419 to learn how Predicine’s Accurate, Accessible, and Affordable (AAA) liquid biopsy solutions can empower your global clinical trials across the US, EU, Japan, China, and beyond.     #ESMO2024 #BreastCancer #CDx #PredicineCARE #PrecisionMedicine 

Join us at ESMO 2024 on September 15th to unveil Predicine’s 7 groundbreaking liquid biopsy studies.     Discover the pivotal role of the PredicineCARE™ urine cfDNA assay in NMIBC patient selection during the TAR210 clinical trial. Explore how the urine-based PredicineBEACON™ personalized MRD assay is revolutionizing treatment response monitoring, along with other key findings.    Visit booth #419 to see how Predicine’s Accurate, Accessible, and Affordable (AAA) liquid biopsy solutions can elevate your global clinical trials across the US, EU, Japan, China, and beyond. #ESMO2024 #PredicineCARE #MRD #PrecisionMedicine #OncologyResearch #CancerTherapeutics #LiquidBiopsy #urine  

Predicine is in Barcelona, Spain, attending #ESMO24! Connect with our team at booth #419 to learn how Predicine's Accurate, Accessible, and Affordable (AAA) liquid biopsy solutions can empower your global clinical trials across the US, EU, Japan, China, and beyond.

Join us at ESMO 2024 for Dr. Matteo Simonelli's mini oral session on the Phase 1 clinical trial of INCB123667, a selective CDK2 inhibitor by Incyte, in advanced solid tumors. Discover key insights into therapy monitoring powered by PredicineSCORE™, a state-of-the-art low-pass whole-genome sequencing assay.    Connect with our team at booth #419 to learn how Predicine’s Accurate, Accessible, and Affordable (AAA) liquid biopsy solutions can empower your global clinical trials across the US, EU, Japan, China, and beyond.     #ESMO2024 #PredicineSCORE #CDK2Inhibitor #PrecisionMedicine #OncologyResearch #CancerTherapeutics #LiquidBiopsy 

Attending ESMO 2024 in Barcelona? Join us at booth #419 to discover how Predicine’s Liquid Biopsy Platform is transforming global clinical trials and CDx development with centralized lab testing and decentralized kitted solutions. Explore 9 ctDNA studies showcasing the clinical utility of Predicine liquid biopsy platform in treatment selection, molecular response, MRD detection, drug resistance, and CDx development. Connect with our team at booth #419 to learn how Predicine’s Accurate, Accessible, and Affordable (AAA) liquid biopsy solutions can empower your global clinical trials across the US, EU, Japan, China, and beyond. #ESMO2024#LiquidBiopsy #ClinicalTrials #CDxDevelopment #Oncology #PrecisionMedicine #Predicine

Explore Predicine's Advanced MRD, CDx, and CSF Solutions at WCLC 2024! Will you attending the 2024 World Conference on Lung Cancer (WCLC) in San Diego? Visit us at Predicine Booth #1420 to discover our pioneering liquid biopsy technologies, including tumor-informed personalized PredicineBEACON™ MRD, the tumor-agnostic methylation-based PredicineALERT™ MRD, and the globally harmonized PredicineCARE™, which has received both FDA Breakthrough Device Designation (BDD) and New York State (NYS) approval. Highlights: MRD: Accelerating Ph1 clinical trial through PredicineBEACON™ • Predicine’s innovative blood-informed, personalized MRD liquid biopsy solution, PredicineBEACON™, has been instrumental in advancing Roche’s Divarasib (KRAS G12C inhibitor) clinical trial. The success of this trial, featured in several high-impact publications including The New England Journal of Medicine, Nature Medicine, and Clinical Cancer Research, highlights our expertise in precision medicine and drug development. CSF Liquid Biopsy: Precision in Lung Cancer Brain Metastasis • Our cerebrospinal fluid (CSF) liquid biopsy technology provides a detailed and accurate approach to detecting genetic mutations, monitoring disease progression, and treatment efficacy in lung cancer brain metastases. This innovative solution tackles one of the most complex clinical challenges. (Journal of Thoracic Oncology, 2024 in press). Clinical trial and CDx: globally harmonized PredicineCARE™ • PredicineCARE™, has earned both FDA Breakthrough Device Designation and New York State approval, is being developed as a companion diagnostics (CDx) for bladder cancer in collaboration with Janssen. Additionally, Predicine is working on an undisclosed CDx project for non-small cell lung cancer (NSCLC). Predicine’s centralized lab testing and decentralized kit solutions support truly global CDx development efforts across the US, EU, Japan, and notably China. We invite you to visit us at Booth #1420 during WCLC to explore collaboration opportunities and discuss how Predicine’s advanced solutions can support your clinical studies, global clinical trials, CDx development, and treatment strategies.